312 related articles for article (PubMed ID: 26874851)
1. Expression of ROR1 has prognostic significance in triple negative breast cancer.
Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
[TBL] [Abstract][Full Text] [Related]
2. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
3. ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.
Zhou JK; Zheng YZ; Liu XS; Gou Q; Ma R; Guo CL; Croce CM; Liu L; Peng Y
Oncotarget; 2017 May; 8(20):32864-32872. PubMed ID: 28427197
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer.
Bolat Kucukzeybek B; Vedat Bayoglu I; Kucukzeybek Y; Alacacioglu A; Yigit S; Akder Sari A; Akyol M; Oktay Tarhan M
J BUON; 2017; 22(4):947-952. PubMed ID: 28952212
[TBL] [Abstract][Full Text] [Related]
7. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
8. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer.
Soljic M; Mrklic I; Tomic S; Omrcen T; Sutalo N; Bevanda M; Vrdoljak E
J Clin Pathol; 2018 Jan; 71(1):34-39. PubMed ID: 28663327
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
11. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
Zheng YZ; Ma R; Zhou JK; Guo CL; Wang YS; Li ZG; Liu LX; Peng Y
Sci Rep; 2016 Nov; 6():36447. PubMed ID: 27830754
[TBL] [Abstract][Full Text] [Related]
12. miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.
Wang X; Qiu H; Tang R; Song H; Pan H; Feng Z; Chen L
Oncol Rep; 2018 Jun; 39(6):2635-2643. PubMed ID: 29693179
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
14. Detecting Receptor Tyrosine Kinase ROR1 Using a Developed Anti-ROR1 Polyclonal Antibody.
Hemmati A; Hassannia H; Milani S; Hadavi R; Ghaemimanesh F; Rabbani H
Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):38-44. PubMed ID: 29474159
[TBL] [Abstract][Full Text] [Related]
15.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
16. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
17. TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer.
Jiang Y; Liu Y; Tan X; Yu S; Luo J
Clin Breast Cancer; 2019 Dec; 19(6):450-455. PubMed ID: 31494045
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition.
Heabah NAE; Darwish SA; Eid AM
Pathol Res Pract; 2023 Aug; 248():154703. PubMed ID: 37481855
[TBL] [Abstract][Full Text] [Related]
19. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
20. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
